Related Experiment Video

Updated: Dec 20, 2025

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome
09:06

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome

Published on: December 12, 2025

134

Use of anakinra in severe COVID-19: A case report

Giovanni Filocamo1, Davide Mangioni2, Paola Tagliabue1

  • 1Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano, Italy.

International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|May 22, 2020
PubMed

Insights

Critical COVID-19 can cause severe inflammation. This case study shows that IL-1 receptor antagonist (anakinra) successfully treated a patient with critical coronavirus disease 2019, reducing hyperinflammation.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • Coronavirus disease 2019 (COVID-19) presents a significant global health challenge with high mortality.
  • Hyperinflammation, characterized by a cytokine storm, is strongly linked to severe COVID-19 outcomes.
  • Interleukin-1 (IL-1) inhibition is a recognized therapeutic strategy for managing hyperinflammatory conditions.

Observation:

  • A patient presented with critical coronavirus disease 2019.
  • The patient experienced severe disease potentially driven by an inflammatory cytokine storm.

Findings:

  • The critical COVID-19 patient was successfully treated with IL-1 receptor antagonist (anakinra).
  • Anakinra effectively targeted the IL-1 pathway, mitigating hyperinflammation.

Implications:

  • IL-1 inhibition, specifically with anakinra, represents a potential therapeutic option for critical COVID-19.
  • This case highlights the role of targeted anti-inflammatory therapies in managing severe infectious diseases.
  • Further research into anakinra for COVID-19 cytokine storm syndrome is warranted.

Keywords:
AnakinraBiologicCOVID-19IL-1Treatment

More Related Videos

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.2K
An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient07:16

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

4.3K

Related Concept Videos

Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
902
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
690
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
115
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
655
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
203
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
365